Literature DB >> 11734093

Actual practice in hypertension: implications for persistence with and effectiveness of therapy.

J D Spence1, T C Hurley, J D Spence1.   

Abstract

Hypertension is often poorly controlled despite its importance and despite the availability of very effective treatments. Many factors contribute to poor control, including failure of patients to attend physicians, failure of physicians to detect and adequately treat hypertension to goal levels, and failure of patients to persist with prescribed therapy. An under-recognized problem is the failure, both in writing and in the application by third party payers, of consensus guidelines to recognize the important difference between efficacy in clinical trials and effectiveness in clinical practice. The issue of applicability of guidelines to actual practice was studied in the context of a Canadian Family Medicine teaching practice. At the time of the study, consensus guidelines for management of hypertension recommended that drug therapy be initiated with a beta-blocker or diuretic, except for patients with complicated hypertension for whom these drug classes are relatively contraindicated. It was generally assumed that widespread use of other classes of drugs represented inappropriate and wasteful use of resources. By a retrospective chart audit, we determined the proportion of patients in a family practice for whom therapy with a beta-blocker or diuretic was contraindicated, and examined the compliance of the physicians in the practice with guidelines. We found that about half of hypertensives had conditions for which recommended therapy is not a beta-blocker or diuretic. Thus, failure of physicians to follow guidelines is apparently less inappropriate than is widely perceived.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734093     DOI: 10.1007/s11906-001-0010-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  25 in total

1.  Low-dose combination therapy: an important first-line treatment in the management of hypertension.

Authors:  J M Neutel; D H Smith; M A Weber
Journal:  Am J Hypertens       Date:  2001-03       Impact factor: 2.689

2.  Poor adherence with hypolipidemic drugs: a lost opportunity.

Authors:  R T Tsuyuki; T J Bungard
Journal:  Pharmacotherapy       Date:  2001-05       Impact factor: 4.705

3.  Factors associated with noncompliance of patients taking antihypertensive medications.

Authors:  E Shaw; J G Anderson; M Maloney; S J Jay; D Fagan
Journal:  Hosp Pharm       Date:  1995-03

4.  Awareness, treatment, and control of hypertension in Canada.

Authors:  M R Joffres; P Ghadirian; J G Fodor; A Petrasovits; A Chockalingam; P Hamet
Journal:  Am J Hypertens       Date:  1997-10       Impact factor: 2.689

5.  Predictors of medication noncompliance in a sample of older adults.

Authors:  S J Coons; S L Sheahan; S S Martin; J Hendricks; C A Robbins; J A Johnson
Journal:  Clin Ther       Date:  1994 Jan-Feb       Impact factor: 3.393

6.  Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference.

Authors:  J S Cohen
Journal:  Arch Intern Med       Date:  2001-03-26

7.  Patients' knowledge and attitude towards treatment and control of hypertension: a nation-wide telephone survey conducted in Malaysia.

Authors:  K L Khoo; Y M Liew; H Tan; J S Sambhi; B A Hatijah
Journal:  Med J Malaysia       Date:  1999-03

8.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

9.  Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

Authors:  L Goldman; M C Weinstein; P A Goldman; L W Williams
Journal:  JAMA       Date:  1991-03-06       Impact factor: 56.272

10.  The direct costs to the NHS of discontinuing and switching prescriptions for hypertension.

Authors:  D Hughes; A McGuire
Journal:  J Hum Hypertens       Date:  1998-08       Impact factor: 3.012

View more
  1 in total

Review 1.  Pharmacoeconomic burden of undertreating hypertension.

Authors:  Luca Degli Esposti; Giorgia Valpiani
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.